Skip to main content
OpenTrials
Completed

NCT Number: NCT05486312

7-week Study With CT-155 in People With Schizophrenia

CT-155 is a novel prescription digital therapeutic (PDT) to treat schizophrenia

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Schizophrenia Mental Disorders Schizophrenia Spectrum and Other Psychotic Disorders

Age range

18 year–64 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CT-155 Study Center, Culver City, California, United States

Loading trial locations.

About this study

CT-155 is a novel prescription digital therapeutic (PDT) being developed by Click Therapeutics, Inc. (Click) and Boehringer Ingelheim (BI) using an interactive, software-based intervention to treat schizophrenia.

This is a multi-center, exploratory, single-arm study to evaluate the feasibility and acceptability of treatment with an abbreviated version of CT-155 in adults diagnosed with schizophrenia. Eligible participants must have a diagnosis of schizophrenia per the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5).

Participants that meet eligibility criteria will be enrolled in the study on Day 1. The study consists of an up to 7-day screening period, a 49-day engagement period, and an up to 7-day follow-up period.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Has outpatient treatment status of schizophrenia.
  • Is on a stable dose of antipsychotic medication(s)
  • Is the solo user of an iPhone with iPhone operating system (iOS)13 or greater capabilities or a smart phone with an Android operating system (OS) 9 or greater capabilities.
  • Is the owner of, and has regular access to, an email address.
  • Has regular access to the internet via cellular data plan and/or wifi.
  • Willing and able to receive SMS text messages on their smartphone and email messages, and understand how to use the downloaded Study App.
  • Has stable housing and has remained at the same residence for at least 12 weeks prior to screening, with no anticipated housing changes during the duration of the study

Exclusion criteria

  • Is currently treated with more than two antipsychotic medications.
  • Is currently treated with clozapine or haloperidol.
  • Has active prominent positive symptoms to preclude effective engagement in treatment for negative symptoms.
  • Is currently receiving or has received psychotherapy within 12 weeks prior to screening.
  • Meets either the International Classification of Diseases (ICD-10) or DSM-5 criteria for diagnoses not under investigation.
  • Has post-traumatic stress disorder (PTSD), bipolar disorder, major depressive disorder, developmental disorders, or any prominent disorder.
  • Has substance or alcohol use disorder.
  • Currently needs or will likely require prohibited concomitant medications.
  • Is currently participating in another clinical study.
  • Prior participation in the CT-155-C-001 clinical study.
  • Has suicidal ideation or behavior.

Treatment and study plan

CT-155 smartphone app

Device

The CT-155 study app is designed to provide treatment monitoring and educational components of a full treatment cycle with CT-155. This design allows inferences to be made about the usability and acceptability of CT-155. Eligible participants will be enrolled during an in-person clinic visit on Day 1. Participants will then be directed to access the study app and perform tasks each day for the 49-day engagement period.

Primary outcomes

  1. Feasibility and acceptability with the study app as measured by Mobile App Rating Scale (MARS) at week 7

    Time frame: MARS scale on Week 7 at the end of the treatment period

    Participants ratings of Study App quality and satisfaction as measured by the Mobile App Rating Scale (MARS) at Week 7

    The MARS is a validated 23-items rated on a 5-point anchored scale 1 being the lowest and 5 the highest

Secondary outcomes

  1. Change in strength of digital working alliance from Week 3 to Week 7 as assessed by the Mobile Agnew Relationships Measure (mARM)

    Time frame: Change from Week 3 to Week 7 of the Mobile Agnew Relationships Measure

    To explore the establishment of a digital working alliance as assessed by the change from Week 3 to Week 7 of the Mobile Agnew Relationships Measure. The Mobile Agnew Relationships Measures is on a 7-item scale that ranges from "Strongly Disagree" as scale 1 to "Strongly Agree" as scale 7.

Sponsors and collaborators

Lead sponsor

Click Therapeutics, Inc.

Industry

Registry information

Official study title

A Multi-center, Exploratory, Single-Arm, 7-week Study to Evaluate the Feasibility and Acceptability of Treatment With CT-155 in People With Schizophrenia

Important dates

Study start
2022
Primary completion
2022
Study completion
2022
First posted
Aug 3, 2022
Registry last updated
May 15, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.